普萘洛尔在严重创伤性颅脑损伤患者中的疗效与安全性研究

doi:10.19854/j.cnki.1008-2425.2025.01.0002

立体定向和功能性神经外科杂志 ›› 2025, Vol. 38 ›› Issue (1): 6-10.DOI: 10.19854/j.cnki.1008-2425.2025.01.0002

普萘洛尔在严重创伤性颅脑损伤患者中的疗效与安全性研究

王杰, 王晓彬, 汤林艳

518000 深圳深圳大学总医院重症医学科(王杰,汤林艳),中国人民解放军联勤保障部队第九七零医院威海医疗区神经外科(王晓彬)

收稿日期:2024-12-05 出版日期:2025-02-25 发布日期:2025-04-17
通讯作者: 王晓彬 wxb18660377325@163.com
基金资助:
深圳大学总医院海雅青年科学家基金项目(编号:2024-HY009)

Study on the efficacy and safety of propranolol in patients with severe traumatic brain injury

Wang Jie¹, Wang Xiaobin², Tang Linyan¹

1. Department of Intensive Care Medicine,Shenzhen University General Hospital,Shenzhen, 518000, China;
2. The 970th Hospital of the Joint Service Support Force of the Chinese People's Liberation Army Weihai Medical District Neurosurgery,Weihai, 264200, China

Received:2024-12-05 Online:2025-02-25 Published:2025-04-17
Contact: Wang Xiaobin wxb18660377325@163.com

摘要/Abstract

摘要： 目的探索肾上腺素能受体抑制剂普萘洛尔治疗严重创伤性脑损伤(severe traumatic brain injury,TBI)患者的安全性和有效性。方法该研究为II期、单中心、双盲、随机对照试验,纳入患者为2022年3月至2024年1月在我院ICU入院24小时内患有严重TBI(颅内出血和格拉斯哥昏迷评分≤8)的患者。患者随机接受普萘洛尔或安慰剂治疗7天。主要结局是28天时无呼吸机天数(ventilator-free days,VFDs)。次要结局包括儿茶酚胺水平、ICU住院时间、住院死亡率。结果两组之间性别分布,年龄,损伤严重度评分(injury severity score,ISS),序贯器官衰竭估计评分(sequential organ failure assessment SOFA)、马歇尔CT分级分布之间均无明显差异,基线资料具有可比性。治疗组和安慰剂组的平均无呼吸机天数(VFD)没有差异(治疗组:14.2±5.3 天vs.安慰剂组:14.5±5.6天)(t=0.277,P=0.783)。此外,两组患者治疗前后血浆儿茶酚胺水平、ICU住院时间(治疗组:20.5±7.3天vs.安慰剂组:20.9±7.9天)(t=0.264,P=0.792)和住院死亡率(治疗组:15.7%vs.安慰剂组:24.0%)(卡方值=1.099,P=0.295)等次要结局差异均无统计学意义。安慰剂组中位生存天数为309天,普萘洛尔组中位生存未达到,两组的生存率存在显著差异(HR=0.453,P=0.043)。两组患者在治疗期间均未出现心脏并发症及其他严重不良事件,治疗组中有1名患者出现暂时性缓慢心律失常,不需要干预,继续药物使用,无患者因不良反应退出研究。结论使用普萘洛尔进行肾上腺素能阻滞治疗严重创伤性脑损伤后是安全可行的,可以给患者带来生存获益。

关键词: 肾上腺素能受体抑制剂, 普萘洛尔, 颅脑损伤, ICU

Abstract: Objective To explore the safety and efficacy of propranolol,an adrenergic receptor inhibitor,in the treatment of severe traumatic brain injury(TBI) patients. Methods This study is a phase II,single center,double-blind,randomized controlled trial that enrolled patients with severe TBI(intracranial hemorrhage and Glasgow Coma Scale ≤8) within 24 hours of admission to our ICU from March 2022 to January 2024.The patient was randomly treated with propranolol or placebo for 7 days.The primary outcome was ventilator free days(VFDs) at 28 days.Secondary outcomes included catecholamine levels,ICU length of stay,and in-hospital mortality. Results There were no significant differences in gender distribution,age,Injury Severity Score(ISS),Sequential Organ Failure Assessment(SOFA),and Marshall CT grading distribution between the two groups,indicating comparability of baseline data.There was no significant difference in the average number of days without ventilators(VFD) between the treatment group and the placebo group(treatment group:14.2±5.3 days vs.placebo group:14.5±5.6 days)(t=0.277,P=0.783).In addition,there were no statistically significant differences in secondary outcomes such as plasma catecholamine levels,ICU length of stay(treatment group:20.5±7.3 days vs.placebo group:20.9±7.9 days)(t=0.264,P=0.792),and in-hospital mortality rate(treatment group:15.7% vs.placebo group:24.0%)(χ²=1.099,P=0.295) between the two groups before and after treatment.The median survival time in the placebo group was 309 days,while the median survival time in the propranolol group was not achieved.There was significant difference in survival rate between the two groups(HR=0.453,P=0.043).During the treatment period,neither group experienced any cardiac complications or other serious adverse events.One patient in the treatment group developed temporary bradycardia,which did not require intervention and continued drug use.No patient withdrew from the study due to adverse reactions. Conclusion The use of propranolol for adrenergic blockade treatment of severe traumatic brain injury is safe and feasible,and brought significant survival benefits to patients.

Key words: Adrenergic receptor inhibitors, Propranolol, Brain injury, ICU

中图分类号:

R651.1

王杰, 王晓彬, 汤林艳. 普萘洛尔在严重创伤性颅脑损伤患者中的疗效与安全性研究[J]. 立体定向和功能性神经外科杂志, 2025, 38(1): 6-10.

Wang Jie, Wang Xiaobin, Tang Linyan. Study on the efficacy and safety of propranolol in patients with severe traumatic brain injury[J]. Chinese Journal of Stereotactic and Functional Neurosurgery, 2025, 38(1): 6-10.

参考文献

[1] 张子川,樊佳,冯贵龙.创伤性脑损伤并发脑心综合征的研究进展[J].中西医结合心脑血管病杂志,2024,22(6):1059~1062.
[2] 杨洪桥,周昭鹏,刘美,等.中重型创伤性脑损伤患者伤后6个月预后不良预测列线图的构建与验证[J].中华创伤杂志,2024,40(6):487~497.
[3] Inaba K,Teixeira PGR,David J-S,et al.Beta-Blockers in isolated blunt head injury[J].J Am Coll Surg,2008,206:432~438.
[4] Arbabi S,Campion EM,Hemmila MR,et al.Beta-Blocker use is associated with improved outcomes in adult trauma patients[J].J Trauma,2007,62:56~62.
[5] Alali AS,Mukherjee K,McCredie VA,et al.Beta-blockers and traumatic brain injury:a systematic review,meta-analysis,and eastern association for the surgery of trauma guideline[J].Ann Surg,2017,266(6):952~961.
[6] Ley EJ,Leonard SD,Barmparas G,et al.Beta blockers in critically ill patients with traumatic brain injury:results from a multicenter,prospective,observational American Association for the Surgery of Trauma study[J].J Trauma Acute Care Surg,2018,84(2):234~244.
[7] Giner J,Mesa Galan L,Yus Teruel S,et al.Traumatic brain injury in the new multicenter:new population and new managemnt[J].Neurologia,2022,37(5):383~389.
[8] 於睿,汪东亮.高压氧治疗对老年大鼠创伤性脑损伤后神经功能的改善作用及相关机制[J].中国老年学杂志,2024,44(6):1438~1441.
[9] Ritter M.Evidence-Based Pearls.Traumatic brain injury[J].Crit Care Nurs Clin North Am,2023,35(2):171~178.
[10] 林颖,余旻,谭香,等.创伤性脑损伤后阵发性交感神经过度兴奋综合征的研究进展[J].临床神经外科杂志,2024,21(2):211~215.
[11] Zeeshan M,Hamidi M,O'Keeffe T,et al.Propranolol attenuates cognitive,learning,and memory deficits in a murine model of traumatic brain injury[J].J Trauma Acute Care Surg,2019,87(5):1140~1147.
[12] Muehlschlegel S,Rajajee V,Wartenberg KE,et al.Guidelines for Neuroprognostication in Critically Ill Adults with Moderate-Severe Traumatic Brain Injury[J].Neurocrit Care,2024,40(2):448~476.
[13] Verdoorn TA,Parry TJ,Pinna G,et al.Neurosteroid receptor modulators for treating traumatic brain injury[J].Neurotherapeutics,2023,20(6):1603~1615.
[14] Cotton BA,Snodgrass KB,Fleming SB,et al.Beta-Blocker exposure is associated with improved survival after severe traumatic brain injury[J].J Trauma,2007,62:26~35.
[15] Schroeppel TJ,Sharpe JP,Shahan CP,et al.Beta-adrenergic blockade for attenuation of catecholamine surge after traumatic brain injury:a randomized pilot trial[J].Trauma Surg Acute Care Open,2019,14(1):e000307.

普萘洛尔在严重创伤性颅脑损伤患者中的疗效与安全性研究

Study on the efficacy and safety of propranolol in patients with severe traumatic brain injury

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 4

编辑推荐

Metrics

本文评价

[1]	魏曙岚, 陈炜钰, 花胜松. 个体化预测重型颅脑损伤患者术后并发脑积水的风险列线图模型的建立[J]. 立体定向和功能性神经外科杂志, 2024, 37(3): 165-170.
[2]	黄弋洋, 李浩, 毛磊, 雷军. 颅内压监测指标预测闭合性颅脑创伤预后的价值[J]. 立体定向和功能性神经外科杂志, 2023, 36(4): 237-241.
[3]	张爱军, 鲁友明, 陈鑫, 袁磊, 邹冬冬. 老年颅脑损伤者术后血清和脑脊液NFL、GFAP对继发交通性脑积水的预测价值[J]. 立体定向和功能性神经外科杂志, 2023, 36(1): 48-54.
[4]	张玉, 李娜, 刘一鸣. 颅脑损伤患儿继发性癫痫危险因素分析及列线图预测模型的构建[J]. 立体定向和功能性神经外科杂志, 2022, 35(2): 95-99.